Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 6, 2008, Pages 1332-1335

  Perrottet, N ^a   Robatel, C ^a   Meylan, P ^a   Pascual, M ^a   Venetz, J P ^a   Aubert, J D ^a   Berger, M M ^a   Decosterd, L A ^a   Buclin, T ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Erythrocytes; Haemofiltration; Pharmacokinetics; Renal failure

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADULT; ARTICLE; CASE REPORT; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISTRIBUTION VOLUME; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TRANSPORT; ERYTHROCYTE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION PREVENTION; KIDNEY FAILURE; LUNG TRANSPLANTATION; MALE; THERAPY EFFECT;

CHEMOPREVENTION; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HALF-LIFE; HUMANS; LUNG TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

EID: 44449129924     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn102     Document Type: Article

References (12)

1. Czock D, Scholle C, Rasche FM et al. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002; 72: 142-50.
2. Perrottet N, Beguin A, Meylan P et al. Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 852: 420-9.
3. Robatel C, Decosterd LA, Biollaz J et al. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol 2003; 43: 1329-40.
4. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-20.
5. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption at ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811-5.
6. Wiltshire H, Hirankam S, Farrell C et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its produrg, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44: 495-507.
7. Chamberlain C, Mannon R, Penzak S et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Transplantation 2006; 82 Suppl 3 WTC Abstracts: 266-7.
8. Boulieu R, Bastein O, Bleyzac N. Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. Ther Drug Monit 1993; 15: 105-7.
9. Bastien O, Boulieu R, Bleyzac N et al. Clinical use of ganciclovir during renal failure and continuous hemodialysis. Intensive Care Med 1994; 20: 47-8.
10. Gando S, Kameue T, Nanzaki S et al. Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. Crit Care Med 1998; 26: 184-7.
11. Mahony WB, Domin BA, Zimmerman TP. Ganciclovir permeation of human erythrocyte membrane. Pharmacology 1991; 41: 263-71.
12. Hinderling PH. Red blood cells: A neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 1997; 49 279-95.